Prime Medicine, Inc.

NasdaqGM:PRME 株式レポート

時価総額：US$556.8m

Prime Medicine 将来の成長

Future 基準チェック /26

Prime Medicineの収益は年間4.6%で減少すると予測されていますが、年間収益は年間41.1%で増加すると予測されています。EPS は年間 増加すると予測されています。自己資本利益率は 3 年後に-183.8% 7.5%なると予測されています。

主要情報

-4.6%

収益成長率

7.46%

EPS成長率

Biotechs 収益成長29.0%
収益成長率41.1%
将来の株主資本利益率-183.76%
アナリストカバレッジ

Good

最終更新日04 Sep 2026

今後の成長に関する最新情報

Recent updates

Seeking Alpha • Aug 11

Prime Medicine: An Initial Prognosis

Summary Prime Medicine possesses promising gene editing technology but faces significant dilution risk and cash constraints, with no new clinical data expected until 2027. PRME's lead programs target high-need liver indications, but both Wilson Disease and AATD programs are preclinical and entering crowded, competitive spaces. The recent tribunal win over Beam Therapeutics clears the path for PM647's clinical entry, yet Beam's accelerated BEAM-302 program may outpace PRME. A prognosis around Prime Medicine follows in the paragraphs below. Read the full article on Seeking Alpha
分析記事 • Jun 18

Is Prime Medicine (NASDAQ:PRME) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Seeking Alpha • Apr 25

Prime Medicine: Initiating Coverage At Hold With 2025 Binary Catalyst For PM359

Summary Initiate Hold on Prime Medicine due to pending Phase 1/2 CGD readout in 2025 and Wilson’s Disease IND filing in 2026, focusing on safety and mechanistic editing. Await six-month durability data in 2026 or clear non-dilutive funding before re-rating, given rising R&D spend and cash runway into mid-2026. PM359 readout seen as a small catalyst; significant share movement depends on demonstrating lasting infection reduction and stable blood counts. The competitive landscape includes Rocket Pharma’s lentiviral RP-L102 and CRISPR Therapeutics’ Cas9-edited HSC trials; PM359’s modular assay development offers lower off-target risk. Read the full article on Seeking Alpha
Seeking Alpha • Feb 05

Prime Medicine: Gene Editing Company, Risky Investment

Summary Prime Medicine, Inc. develops prime editing technologies but lacks proof of concept data despite being in the market for 6 years and IPO for 3 years. The gene editing sector is highly risky, with poor performers like Editas Medicine and Beam Therapeutics highlighting the volatility and challenges in clinical success. PRME's financials show a market cap of $338mn and a cash runway into 2026, but significant risks remain if clinical data is not favorable. Despite some positive developments, including a partnership with Bristol Myers Squibb, retail investors should exercise caution due to the high risk and low cash runway. Read the full article on Seeking Alpha
分析記事 • Dec 19

Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Nov 26

Prime Medicine's Bristol Myers Partnership Boosts Outlook For Gene Editing Therapies

Summary Prime Medicine’s proprietary Prime Editing platform offers one-time therapeutic solutions, targeting over 90% of genetic conditions across multiple tissues and development stages. PRME’s pipeline highlights PM359 for chronic granulomatous disease and preclinical programs for Wilson’s Disease, with clinical data expected in 2025. PRME's strategic collaboration with Bristol Myers provided $55 million in cash upfront, a $55 million equity stake, $3.5B in potential milestone payments, and diversification into ex vivo T-cell therapies. Still, investment risks include dependency on milestone achievements and potential future equity raises, but current valuation and prospects make PRME a compelling investment. Despite remaining speculative, PRME’s improved financial position, strategic partnerships, and pipeline progress justify an upgraded "Buy" rating. Read the full article on Seeking Alpha
Seeking Alpha • Sep 04

Prime Medicine's Promising Pipeline: PM359 And Cash Burn Concerns

Summary Prime Medicine's Prime Editing offers precise, adaptable, and safer gene-editing treatments, with PM359 for Chronic Granulomatous Disease recently cleared for clinical trials. PRME’s lead drug candidate, PM359, was cleared by the FDA in April 2024 and is in Phase 1/2 clinical trials for Chronic Granulomatous Disease. PRME's short-term liquidity is $162.9 million, but its high cash burn suggests it'll need additional financing in the near term. I rate PRME as a “Hold” due to its promising technology but significant cash burn and dilution risks. Read the full article on Seeking Alpha
分析記事 • Sep 04

Here's Why We're A Bit Worried About Prime Medicine's (NASDAQ:PRME) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jun 20

Prime Medicine Stock: Only For The Most Patient Of Investors

Summary We take our first look at gene editing concern Prime Medicine, Inc., whose stock was recently upgraded by Citigroup. The company has an extensive set of potential candidates in pre-clinical research and just advanced its first gene therapy asset in clinical stage development. An analysis around Prime Medicine follows in the paragraphs below. Read the full article on Seeking Alpha
分析記事 • May 14

Is Prime Medicine (NASDAQ:PRME) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jan 28

Prime Medicine's Investment Potential: A Deep Dive Into Innovation And Gene Editing

Summary Prime Medicine is a gene editing company at the forefront of genetic therapies, with a promising pipeline and preclinical successes. The company has made substantial investments in R&D, demonstrating its commitment to innovation and belief in its technology. Despite financial losses, Prime Medicine maintains a strong cash position, providing stability and flexibility for future growth. Read the full article on Seeking Alpha
分析記事 • Aug 25

Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • May 12

We're Not Very Worried About Prime Medicine's (NASDAQ:PRME) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
分析記事 • Jan 24

Will Prime Medicine (NASDAQ:PRME) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

業績と収益の成長予測

NasdaqGM:PRME - アナリストの将来予測と過去の財務データ ( )USD Millions
日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数
12/31/202819-219-251-18712
12/31/202713-204-189-16814
12/31/202612-182-158-13814
6/30/20264-188-157-156N/A
3/31/20264-198-159-156N/A
12/31/20255-201-167-163N/A
9/30/20256-197-115-109N/A
6/30/20255-199-107-100N/A
3/31/20254-202-111-104N/A
12/31/20243-196-130-123N/A
9/30/20241-219-190-183N/A
6/30/20241-217-205-196N/A
3/31/20241-204-201-192N/A
12/31/2023N/A-198-174-165N/A
9/30/2023N/A-173-164-152N/A
6/30/2023N/A-158-157-143N/A
3/31/2023N/A-151-139-123N/A
12/31/2022N/A-142-148-132N/A
9/30/2022N/A-171-126-114N/A
6/30/2022N/A-158-103-94N/A
3/31/2022N/A-126-85-80N/A
12/31/2021N/A-184-38-34N/A
9/30/2021N/A-118-27-23N/A
12/31/20205-5-6-6N/A

アナリストによる今後の成長予測

収入対貯蓄率: PRME今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: PRME今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: PRME今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: PRMEの収益 ( 41.1% ) US市場 ( 13.4% ) よりも速いペースで成長すると予測されています。

高い収益成長: PRMEの収益 ( 41.1% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: PRME 3 年以内に赤字になると予測されています。

成長企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/09/13 02:03
終値2026/09/11 00:00
収益2026/06/30
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した ご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Prime Medicine, Inc. 14 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。19

アナリスト機関
Keay NakaeChardan Capital Markets, LLC
Yevgeniya LivshitsChardan Capital Markets, LLC
Samantha Lynn SemenkowCitigroup Inc